{"id":"https://openalex.org/W4310108165","doi":"https://doi.org/10.1182/blood-2022-167410","title":"AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis","display_name":"AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310108165","doi":"https://doi.org/10.1182/blood-2022-167410"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-167410","doi":"https://doi.org/10.1182/blood-2022-167410","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-167410","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. DeAngelo","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021124944","display_name":"Andreas Reiter","orcid":"https://orcid.org/0000-0002-7718-6507","observed_orcids":["https://orcid.org/0000-0002-7718-6507"]},"institutions":[{"id":"https://openalex.org/I4210156450","display_name":"University Medical Centre Mannheim","ror":"https://ror.org/05sxbyd35","country_code":"DE","type":"funder","lineage":["https://openalex.org/I4210156450"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Andreas Reiter","raw_affiliation_strings":["2Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany","institution_ids":["https://openalex.org/I4210156450"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015788207","display_name":"Tracy I. George","orcid":"https://orcid.org/0000-0001-5478-7847","observed_orcids":["https://orcid.org/0000-0001-5478-7847"]},"institutions":[{"id":"https://openalex.org/I61474668","display_name":"ARUP Laboratories (United States)","ror":"https://ror.org/00c2tyx86","country_code":"US","type":"company","lineage":["https://openalex.org/I61474668"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tracy I. George","raw_affiliation_strings":["3ARUP Laboratories, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3ARUP Laboratories, Salt Lake City, UT","institution_ids":["https://openalex.org/I61474668"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028061272","display_name":"Deepti H. Radia","orcid":"https://orcid.org/0000-0002-3578-0102","observed_orcids":["https://orcid.org/0000-0002-3578-0102"]},"institutions":[{"id":"https://openalex.org/I1298207432","display_name":"Guy's Hospital","ror":"https://ror.org/04r33pf22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1298207432","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Deepti H. Radia","raw_affiliation_strings":["4Department of Clinical Haematology, Guy's & St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Clinical Haematology, Guy's & St Thomas\u2019 NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1298207432","https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Marissa Devlin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marissa Devlin","raw_affiliation_strings":["5Blueprint Medicines Corporation, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Blueprint Medicines Corporation, Cambridge, MA","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111904985","display_name":"Sa\u0161a Dimitrijevi\u0107","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sa\u0161a Dimitrijevi\u0107","raw_affiliation_strings":["6Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015677091","display_name":"Mikael L. Rinne","orcid":"https://orcid.org/0009-0006-6764-9404","observed_orcids":["https://orcid.org/0009-0006-6764-9404"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikael Rinne","raw_affiliation_strings":["5Blueprint Medicines Corporation, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Blueprint Medicines Corporation, Cambridge, MA","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017460979","display_name":"Robyn Marie Scherber","orcid":"https://orcid.org/0000-0001-7343-5679","observed_orcids":["https://orcid.org/0000-0001-7343-5679"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robyn Scherber","raw_affiliation_strings":["5Blueprint Medicines Corporation, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Blueprint Medicines Corporation, Cambridge, MA","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065621786","display_name":"Jason R. Gotlib","orcid":"https://orcid.org/0000-0001-8253-6156","observed_orcids":["https://orcid.org/0000-0001-8253-6156"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Gotlib","raw_affiliation_strings":["7Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":1.247,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.77576664,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"6877","last_page":"6878"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/systemic-mastocytosis","display_name":"systemic mastocytosis","score":0.9139999747276306},{"id":"https://openalex.org/keywords/advanced-systemic-mastocytosis","display_name":"advanced systemic mastocytosis","score":0.8790000081062317},{"id":"https://openalex.org/keywords/mast-cell-leukemia","display_name":"mast cell leukemia","score":0.8450000286102295},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.9750000238418579},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.968999981880188},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7139999866485596},{"id":"https://openalex.org/keywords/recommended-dose","display_name":"recommended dose","score":0.5080000162124634},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.7760000228881836},{"id":"https://openalex.org/keywords/kit-d816v-mutation","display_name":"KIT D816V mutation","score":0.8009999990463257},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.3700000047683716}],"concepts":[{"id":"https://openalex.org/C2780581156","wikidata":"https://www.wikidata.org/wiki/Q112670","display_name":"Systemic mastocytosis","level":3,"score":0.8562440276145935},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7938433885574341},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.6046733856201172},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5149334073066711},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.45998185873031616},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43732312321662903},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41931912302970886},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4108855426311493},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4046207070350647},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3691689372062683},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.23988783359527588},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-167410","doi":"https://doi.org/10.1182/blood-2022-167410","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-167410","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4210290474","https://openalex.org/W2739860316","https://openalex.org/W4283714704","https://openalex.org/W3212096504","https://openalex.org/W4415829642","https://openalex.org/W2940001958","https://openalex.org/W4405096109","https://openalex.org/W4310109036","https://openalex.org/W4389231326","https://openalex.org/W2572162671"],"abstract_inverted_index":{"Background:":[0],"Systemic":[1],"mastocytosis":[2],"(SM)":[3],"is":[4,41,50,77],"a":[5,52,80,107,284,323,377],"clonal":[6],"hematologic":[7,73,378],"neoplasm,":[8],"which":[9,60],"leads":[10],"to":[11,45,119,187,208,229,269,421,442],"proliferation":[12],"and":[13,30,49,68,86,126,144,151,173,213,260,292,311,380,391,404,410,434,449],"accumulation":[14],"of":[15,47,62,83,96,106,146,154,193,216,250,256,265,290,299,328,401,407,432,445,452],"mast":[16,65],"cells":[17],"(MCs)":[18],"in":[19,43,56,129,157,167,218,236,425],"multiple":[20],"body":[21],"organs":[22],"(the":[23],"skin,":[24],"bone":[25],"marrow":[26],"[BM],":[27],"spleen,":[28],"liver,":[29],"gastrointestinal":[31],"tract)":[32],"causing":[33],"end":[34],"organ":[35],"damage.":[36],"The":[37,104],"KIT":[38,110,155],"D816V":[39,111,156],"mutation":[40],"identified":[42],"up":[44],"95%":[46],"patients":[48,88,158,177,207,232,243,279,320,375,453],"therefore":[51],"major":[53],"therapeutic":[54],"target":[55],"advanced":[57],"SM":[58,69],"(AdvSM)":[59],"consists":[61],"aggressive":[63],"SM,":[64],"cell":[66,458],"leukemia,":[67],"with":[70,79,89,113,159,169,182,203,343,368,376,388],"an":[71,114,117,133,148,204,221],"associated":[72,78],"neoplasm":[74,379],"(SM-AHN).":[75],"SM-AHN":[76],"high":[81,90],"degree":[82],"genetic":[84],"heterogeneity":[85],"some":[87],"risk":[91],"AHNs":[92],"require":[93],"the":[94,142,189,211,237,266,271,297,338,389,402,450],"use":[95],"AHN-directed":[97],"therapy,":[98,415],"such":[99],"as":[100,162,164,166,416,418],"hypomethylating":[101],"agents":[102],"(HMAs).":[103],"combination":[105,168,238,293,339,384,414],"highly":[108],"selective":[109,152],"inhibitor":[112,153],"HMA":[115],"represents":[116],"opportunity":[118],"improve":[120],"response":[121,392,423,439],"by":[122,200],"inhibiting":[123],"both":[124,161],"MC":[125],"AHN":[127],"clones":[128],"high-risk":[130,350],"patients.":[131],"AZURE,":[132],"international":[134],"phase":[135,364],"1/2,":[136],"open-label,":[137],"2-arm":[138],"study,":[139],"will":[140,178,197,244,280,295],"evaluate":[141],"safety":[143,212,285,405],"efficacy":[145,215,419],"BLU-263,":[147],"orally":[149],"administered":[150],"AdvSM,":[160],"monotherapy":[163,185,224,267,291,409],"well":[165,417],"azacitidine.":[170],"Study":[171],"design":[172],"methods:":[174],"Approximately":[175],"18":[176,242],"initially":[179],"be":[180,198,230,281],"treated":[181],"escalating":[183],"BLU-263":[184,194,217,223,261,408,411,433,435],"doses":[186,249],"determine":[188,270],"recommended":[190],"dose":[191,201,225,268],"(RD)":[192],"(RDmono).":[195],"This":[196],"followed":[199],"expansion":[202,286],"additional":[205,278],"13":[206],"further":[209],"characterize":[210],"preliminary":[214],"AdvSM.":[219,426],"Once":[220],"initial":[222],"has":[226],"been":[227],"demonstrated":[228],"safe,":[231],"may":[233],"begin":[234],"enrollment":[235],"arm,":[239],"where":[240,395],"approximately":[241,276],"receive":[245],"standard":[246],"azacitidine":[247,413],"at":[248,263],"75":[251],"mg/m2/day":[252],"on":[253],"days":[254],"1-7":[255],"each":[257],"28-day":[258],"cycle,":[259],"starting":[262],"50%":[264],"RDcombo.":[272],"After":[273],"RDcombo":[274],"determination,":[275],"10":[277],"enrolled":[282],"into":[283],"cohort.":[287],"Dose":[288],"escalation":[289],"therapy":[294,340],"follow":[296],"rules":[298],"Bayesian":[300],"optimal":[301],"interval":[302],"design.":[303],"Key":[304],"eligibility":[305],"criteria":[306,424],"include":[307,341,399,429],"age":[308],"\u226518":[309],"years":[310],"Eastern":[312],"Cooperative":[313],"Oncology":[314],"Group":[315],"performance":[316],"status":[317],"0-3.":[318],"Eligible":[319],"must":[321],"have":[322],"centrally":[324],"confirmed":[325],"pathologic":[326],"diagnosis":[327],"AdvSM":[329],"per":[330,354],"World":[331],"Health":[332],"Organization":[333],"criteria.":[334],"Patients":[335],"eligible":[336],"for":[337,359,383],"those":[342],"chronic":[344],"myelomonocytic":[345],"leukemia-2;":[346],"high-":[347],"or":[348,374],"very":[349],"myelodysplastic":[351],"syndrome":[352],"(MDS)":[353],"International":[355],"Prognostic":[356],"Scoring":[357],"System":[358],"Myelodysplastic":[360],"Syndromes-Revised":[361],"(IPSS-R);":[362],"accelerated":[363],"myeloproliferative":[365],"neoplasm;":[366],"MDS":[367],"excessive":[369],"blasts-2;":[370],"complex":[371],"karyotype/mutational":[372],"profile;":[373],"strong":[381],"rationale":[382],"treatment":[385],"following":[386],"consultation":[387],"sponsor":[390],"assessment":[393],"committee":[394],"needed.":[396],"Primary":[397],"endpoints":[398,428],"determination":[400],"RD":[403],"profile":[406],"+":[412,436],"according":[420],"established":[422],"Secondary":[427],"pharmacokinetic":[430],"parameters":[431],"azacitidine,":[437],"overall":[438],"rate,":[440],"time":[441],"response,":[443,446],"duration":[444],"progression-free":[447],"survival,":[448],"proportion":[451],"pursuing":[454],"allogeneic":[455],"hematopoietic":[456],"stem":[457],"transplantation.":[459],"Figure":[460],"1View":[461,464],"largeDownload":[462,465],"PPTFigure":[463],"PPT":[466],"Close":[467],"modal":[468]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":6}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-11-30T00:00:00"}